{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T12:22:52Z","timestamp":1784809372229,"version":"3.55.0"},"reference-count":20,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2000,3,1]],"date-time":"2000-03-01T00:00:00Z","timestamp":951868800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,12,29]],"date-time":"2014-12-29T00:00:00Z","timestamp":1419811200000},"content-version":"vor","delay-in-days":5416,"URL":"https:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Microbiology and Infection"],"published-print":{"date-parts":[[2000,3]]},"DOI":"10.1046\/j.1469-0691.2000.00014.x","type":"journal-article","created":{"date-parts":[[2003,3,11]],"date-time":"2003-03-11T07:20:56Z","timestamp":1047367256000},"page":"117-120","source":"Crossref","is-referenced-by-count":34,"title":["Monitoring plasma levels of ganciclovir in AIDS patients receiving oral ganciclovir as maintenance therapy for CMV retinitis"],"prefix":"10.1016","volume":"6","author":[{"given":"C.","family":"Piketty","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Bardin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Gilquin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Gairard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.D.","family":"Kazatchkine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Chast","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1046\/j.1469-0691.2000.00014.x_bib1","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1093\/infdis\/166.6.1223","article-title":"Incidence and natural history of CMV disease in patients with advanced human immunodeficiency virus disease treated with zidovudine. The Zidovudine Epidemiol Study Group","volume":"166","author":"Gallant","year":"1992","journal-title":"J Infect Dis"},{"key":"10.1046\/j.1469-0691.2000.00014.x_bib2","doi-asserted-by":"crossref","first-page":"585","DOI":"10.7326\/0003-4819-108-4-585","article-title":"Serious cytomegalovirus disease in the acquired immunodeficiency syndrome (AIDS). clinical findings, diagnosis, and treatment","volume":"108","author":"Jacobson","year":"1988","journal-title":"Ann Intern Med"},{"key":"10.1046\/j.1469-0691.2000.00014.x_bib3","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1093\/infdis\/155.2.323","article-title":"Use of ganciclovir to treat serious infections in patients with AIDS","volume":"155","author":"Laskin","year":"1987","journal-title":"J Infect Dis"},{"key":"10.1046\/j.1469-0691.2000.00014.x_bib4","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1056\/NEJM199509073331002","article-title":"Oral ganciclovir as maintenance treatment for cytomegalovirus retinitis in patients with AIDS","volume":"333","author":"Drew","year":"1995","journal-title":"N Engl J Med"},{"key":"10.1046\/j.1469-0691.2000.00014.x_bib5","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1097\/00002030-199505000-00009","article-title":"Intravenous versus oral ganciclovir. European and Australian comparative study of efficacy and safety in the prevention of cytomegalovirus retinitis recurrence in patients with AIDS","volume":"9","year":"1995","journal-title":"AIDS"},{"key":"10.1046\/j.1469-0691.2000.00014.x_bib6","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1056\/NEJM199606063342302","article-title":"Oral ganciclovir for the prevention of cytomegalovirus disease in persons with AIDS","volume":"334","author":"Spector","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1046\/j.1469-0691.2000.00014.x_bib7","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1093\/infdis\/174.1.188","article-title":"Low plasma concentrations achieved with conventional schedules of administration of ganciclovir with AIDS","volume":"174","author":"Piketty","year":"1996","journal-title":"J Infect Dis"},{"key":"10.1046\/j.1469-0691.2000.00014.x_bib8","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/0149-2918(95)80107-3","article-title":"Ganciclovir absolute bioavailability and steady-state pharmacokinetics after oral administration of two 3000-mg\/d dosing regimens in human immunodeficiency virus- and cytomegalovirus-seropositive patients","volume":"17","author":"Anderson","year":"1995","journal-title":"Clin Ther"},{"key":"10.1046\/j.1469-0691.2000.00014.x_bib9","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1093\/infdis\/171.6.1431","article-title":"Pharmacokinetic, safety, and antiviral profiles of oral ganciclovir in persons infected with human immunodeficiency virus: a phase I\/II study","volume":"171","author":"Spector","year":"1995","journal-title":"J Infect Dis"},{"issue":"Suppl. 4","key":"10.1046\/j.1469-0691.2000.00014.x_bib10","first-page":"S3","article-title":"Pharmacokinetics of oral ganciclovir capsules in HIV-infected persons","volume":"10","author":"Griffy","year":"1996","journal-title":"AIDS"},{"key":"10.1046\/j.1469-0691.2000.00014.x_bib11","series-title":"Proceedings of the 22nd European Symposium on Clinical Pharmacy","first-page":"114","article-title":"Clinical activity and toxicity related to ganciclovir concentrations","author":"Bardin","year":"1993"},{"issue":"Suppl. 3","key":"10.1046\/j.1469-0691.2000.00014.x_bib12","doi-asserted-by":"crossref","first-page":"S547","DOI":"10.1093\/clinids\/10.Supplement_3.S547","article-title":"Ganciclovir therapy for cytomegalovirus infections in recipients of bone marrow transplants and other immunosuppressed patients","volume":"10","author":"Winston","year":"1988","journal-title":"Rev Infect Dis"},{"issue":"Suppl. 3","key":"10.1046\/j.1469-0691.2000.00014.x_bib13","doi-asserted-by":"crossref","first-page":"S507","DOI":"10.1093\/clinids\/10.Supplement_3.S507","article-title":"Clinical pharmacokinetics of ganciclovir in patients with normal and impaired renal function","volume":"10","author":"Sommadossi","year":"1988","journal-title":"Rev Infect Dis"},{"key":"10.1046\/j.1469-0691.2000.00014.x_bib14","doi-asserted-by":"crossref","first-page":"2350","DOI":"10.1128\/AAC.39.10.2350","article-title":"Population differences in ganciclovir clearance as determined by nonlinear mixed-effects modelling","volume":"39","author":"Yuen","year":"1995","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1046\/j.1469-0691.2000.00014.x_bib15","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1056\/NEJM198902023200505","article-title":"Progressive disease due to ganciclovir resistant cytomegalovirus in immuno-compromised patients","volume":"320","author":"Erice","year":"1989","journal-title":"N Engl J Med"},{"key":"10.1046\/j.1469-0691.2000.00014.x_bib16","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1128\/AAC.25.2.247","article-title":"Effect of the nucleoside analog 2\u2032 nor 2\u2032 deoxyguanosine on human cytomegalovirus infection","volume":"25","author":"Tocci","year":"1984","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1046\/j.1469-0691.2000.00014.x_bib17","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1093\/infdis\/152.4.833","article-title":"Sensitivity of clinical isolates of human cytomegalovirus to 9-(1,3-dihydroxy-2-propoxymethyl) guanine","volume":"152","author":"Plotkin","year":"1985","journal-title":"J Infect Dis"},{"key":"10.1046\/j.1469-0691.2000.00014.x_bib18","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/0732-8893(87)90020-4","article-title":"In vitro susceptibility of cytomegalovirus isolates from immunocompromised patients to acyclovir and ganciclovir","volume":"6","author":"Cole","year":"1987","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1046\/j.1469-0691.2000.00014.x_bib19","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1007\/s004670050391","article-title":"Prophylactic oral ganciclovir after renal transplantation-dosing and pharmacokinetics","volume":"12","author":"Filler","year":"1998","journal-title":"Pediatr Nephrol"},{"key":"10.1046\/j.1469-0691.2000.00014.x_bib20","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1086\/314747","article-title":"Cytomegalovirus (CMV) resistance in patients with CMV retinitis and AIDS treated with oral or intravenous ganciclovir","volume":"179","author":"Drew","year":"1999","journal-title":"J Infect Dis"}],"container-title":["Clinical Microbiology and Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X14644943?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X14644943?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,4,12]],"date-time":"2019-04-12T00:22:11Z","timestamp":1555028531000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1198743X14644943"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2000,3]]},"references-count":20,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2000,3]]}},"alternative-id":["S1198743X14644943"],"URL":"https:\/\/doi.org\/10.1046\/j.1469-0691.2000.00014.x","relation":{},"ISSN":["1198-743X"],"issn-type":[{"value":"1198-743X","type":"print"}],"subject":[],"published":{"date-parts":[[2000,3]]}}}